Pharmaceutical Technology

JULY 11, 2023

Astellas Pharma has entered into an agreement to license 4DMT's R100 vector for a genetic target associated with rare ophthalmic ailments.

Licensing 100

Licensing Licensing Genetics 100

Pharmaceutical Technology

OCTOBER 25, 2022

There are options in the future to possibly apply the worldwide research and development (R&D), manufacturing and marketing expertise of Astellas in gene therapy to AAV gene therapy development programmes of Taysha for genetic ailments of the central nervous system (CNS).

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

pharmaphorum

NOVEMBER 15, 2022

Jnana said in a statement that the funding will allow it to take JNT-517 through proof-of-concept testing in PKU, a genetic disorder caused by an inability to break down the amino acid phenylalanine in the diet that can lead to serious neurological and neuropsychological symptoms if untreated.

Licensing 105

Licensing Licensing Protein Genetics 105

XTalks

DECEMBER 4, 2024

These efforts aim to fast-track commercialization and out-licensing agreements in one of the world’s most promising pharmaceutical markets. CAMP4’s RNA-based therapies focus on genetic diseases like urea cycle disorders, while Rapport’s small molecules aim to address epilepsy, pain and bipolar disorder.

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. The option licensing agreement is based on early-stage clinical results.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

XTalks

FEBRUARY 4, 2025

Related: FDA Approves New Use for Ozempic to Reduce the Risks of Kidney Disease Maze stands out in the biotech space with its Compass platform, which analyzes genetic data to identify disease-linked variants. For complex diseases like chronic kidney disease (CKD), where genetics play a significant role, such a platform holds promise.

Clinical Trials 66

Clinical Trials Clinical Trials Trials Genetics 66

XTalks

AUGUST 9, 2022

Innova Medical Group, the world’s largest COVID-19 test provider, has secured the licensing rights for commercializing a new COVID-19 testing technology developed at the University of Birmingham. Innova Medical Group, which secured the licensing rights for the test, is the world’s largest provider of lateral flow tests.

Licensing 98

Licensing Licensing DNA RNA 98

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

JUNE 13, 2023

The British investment trust Syncona Limited launched the new ophthalmic gene therapy company by combining Applied Genetic Technologies Corporation’s (AGTC’s) late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary preclinical programmes. Beacon Therapeutics is the third gene therapy company Syncona has launched.

Gene Therapy 246

Gene Therapy Gene Trials Clinical Trials 246

BioTech 365

NOVEMBER 11, 2021

Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited … Continue reading →

Licensing 40

Licensing Licensing Genetics 40

BioTech 365

APRIL 15, 2021

Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically … Continue reading →

Licensing 40

Licensing Licensing Genetics Development 40

XTalks

JUNE 20, 2022

Alnylam’s Onpattro was its first licensed and approved RNAi therapy for ATTR polyneuropathy. Results of the study show that the RNAi therapeutic significantly improved the signs and symptoms of polyneuropathy and 50 percent of patients achieved a cease or reversal of their disease manifestations.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

STAT News

FEBRUARY 21, 2023

BEIJING — Hong Kong on Tuesday revoked a visa it granted to a Chinese scientist who set off an ethical debate five years ago with claims that he made the world’s first genetically edited babies, pulling it hours after he announced his research plans in the financial hub. Read the rest…

Scientist 98

Scientist Genetics Licensing Licensing 98

Worldwide Clinical Trials

NOVEMBER 27, 2023

Food and Drug Administration (FDA) announced its acceptance of the Biologics License Application (BLA) for exa-cel. sickle cell disease community and the millions around the globe who suffer from this genetic illness. In June 2023, the U.S.

Gene Editing 189

Gene Editing Gene Gene Therapy In-Vivo 189

Pharmaceutical Technology

JANUARY 5, 2023

Under the multi-year strategic partnership, Prevail will detect and advance capsids, which are clinically translatable, along with its cargo to develop the transformative genetic medicines by using Capsida’s novel adeno-associated virus (AAV) engineering platform.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

XTalks

APRIL 3, 2025

Eli Lilly shared new Phase II trial data showing that its experimental siRNA therapy, lepodisiran, leads to reductions in levels of lipoprotein(a) (Lp(a)) a genetically inherited risk factor for heart disease in adults with elevated levels of the marker. High Lp(a) levels can double or even triple the risk of a heart attack.

Trials 59

Trials Clinical Trials Clinical Trials Genetics 59

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D).

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Pharmaceutical Technology

JULY 7, 2022

The US Food and Drug Administration (FDA) has granted priority review to Roche’s Biologics License Application (BLA) of Lunsumio (mosunetuzumab) to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL). These patients should have received a minimum of two prior systemic therapies.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Licensing 162

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs. ImmunoForge will expedite the development of new drugs based on the elastin-like polypeptide (ELP) platform technology originally developed by Duke’s Professor Ashutosh Chilkoti.

Development 130

Development Drugs Licensing Licensing 130

The Pharma Data

SEPTEMBER 15, 2020

MSD has signed two new oncology-based deals with Seattle Genetics which together could be worth up to around $4.4 For this, MSD will put up $600 million up front and a $1 billion equity investment for five million of Seattle Genetics’ shares, while the latter will also have the option to scoop up an additional $2.6 Matt Fellows.

Genetics 52

Genetics Development Hormones Licensing 52

Pharmaceutical Technology

AUGUST 24, 2022

Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. .

Development 130

Development Gene Therapy Genetics Gene 130

BioTech 365

JULY 26, 2021

ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models DUBLIN & SHIZUOKA, Japan–(BUSINESS WIRE)–ERS Genomics Limited, … Continue reading →

Genome 40

Genome Genomics Licensing Licensing 40

BioTech 365

MARCH 9, 2021

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS … Continue reading →

Genomics 40

Genomics Genome Licensing Licensing 40

pharmaphorum

DECEMBER 7, 2021

AZ has previously licensed rights to several other Ionis antisense drugs – including candidates for cholesterol-lowering, non-alcoholic steatohepatitis (NASH), chronic kidney disease, and cancer – but this is the first time that it has gone after a candidate already in late-stage development.

Licensing 59

Licensing Licensing Drugs Marketing 59

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. SK bioscience is manufacturing Nuvaxovid’s drug substance, and drug product for domestic use after the companies signed a licensing agreement in Korea.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Pharmaceutical Technology

SEPTEMBER 22, 2022

AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein. Avrobio has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, AVR-RD-04, designed to treat cystinosis.

Gene Therapy 147

Gene Therapy Gene Protein Clinical Trials 147

Pharmaceutical Technology

NOVEMBER 10, 2022

In 2016, it was licensed by the company to Amgen. The siRNA therapy is created to reduce lipoprotein(a) [Lp(a)] levels, which is a genetically decided, independent cardiovascular disease risk factor. The rights to development, regulatory and sales milestone payments of $400m due from Amgen will be retained by Arrowhead.

RNA 130

RNA Sales Clinical Trials Clinical Trials 130

pharmaphorum

OCTOBER 25, 2022

The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene therapies for rare genetic diseases. ” The post Astellas makes another gene therapy play, takes stake in Taysha appeared first on.

Gene Therapy 104

Gene Therapy Gene Genetic Disease Genetics 104

Pharmaceutical Technology

MAY 24, 2023

It is also licensed by Spain’s Centro de Investigación Biomédica en Red de Enfermedades Raras, the Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz and the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The therapy has also received orphan drug and fast-track designations.

Gene Therapy 130

Gene Therapy Gene Licensing Licensing 130

Pharmaceutical Technology

AUGUST 16, 2022

In July, the US Food and Drug Administration (FDA) approved Horizon’s supplemental Biologics License Application for Krystexxa (pegloticase) plus methotrexate, to aid uncontrolled gout patients attain a complete response to treatment.

Development 130

Development Clinical Trials Clinical Trials Regulation 130

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. “We

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

Delveinsight

JANUARY 12, 2021

Medivir, IGM Biosciences enters into an exclusive licensing agreement for Birinapant. Medivir AB has entered into an exclusive licensing agreement with IGM Biosciences to receive global, exclusive development rights for Birinapant. AvantGen Enters into a Licensing Agreement for its Anti-SARS-CoV-2 Antibodies with IGM Biosciences.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

XTalks

MAY 5, 2022

The Paleo certification program is based on the organization’s principle of encouraging the avoidance of dairy products, genetically modified organisms (GMO’s), grains, highly processed foods and legumes, among other foods. Licensing is available through The Valen Group, the organization’s exclusive licensing partner.

Packaging 98

Packaging Packaging Licensing Licensing 98

BioTech 365

SEPTEMBER 21, 2020

– Data Featured in Late-Breaking Proffered Paper Oral Presentation – – Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA – BOTHELL, Wash. & & COPENHAGEN, Denmark–(BUSINESS WIRE)–Seattle Genetics, Inc.

Genetics 40

Genetics Licensing Licensing Trials 40

Delveinsight

DECEMBER 8, 2020

KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus. KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market.

Licensing 52

Licensing Licensing Gene Therapy Antibody 52

pharmaphorum

MAY 4, 2022

Once selected, Quris can in-license them, progress them through to phase 1 trials and, those that succeed, can be licensed to pharma companies. Once the initial drug candidate is licensed to a pharma company, the profits are then shared with the academic institution or biotech from which Quris originally licensed the drug.

Drugs 143

Drugs Licensing Licensing Pharma Companies 143